xaluritamig

Xaluritamig (AMG 509) is a bispecific T-cell engager (BiTE) designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is engineered to simultaneously bind to the Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1), which is highly expressed on the surface of prostate cancer cells, and the CD3 epsilon subunit of the T-cell receptor complex. By bridging these two targets, xaluritamig facilitates the recruitment and activation of cytotoxic T-cells, leading to the selective lysis of STEAP1-expressing tumor cells. Developed by Amgen using Xencor's XmAb bispecific Fc technology, the molecule features an engineered Fc domain to extend its serum half-life and enhance stability. It is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with advanced prostate cancer who have progressed on standard therapies.

Other names

STEAP1 x CD3 bispecific antibodySTEAP-1 x CD3 bispecific antibodySTEAP 1 x CD3 bispecific antibody